Idorsia Ltd and Syneos Health have entered into a commercial relationship for the US commercialization of Idorsia’s daridorexant, a new dual orexin receptor antagonist being investigated for the treatment of insomnia. The strategic collaboration brings Idorsia’s lead investigational compound, daridorexant, and expertise in the science of the orexin system, together with Syneos Health’s customer-facing sales expertise and track record in launching new products in the United States.

Simon Jose, chief commercial officer of Idorsia, says in a release, “Idorsia has discovered and developed a sleep medicine that, for the first time, has demonstrated in pivotal studies not only an improvement in sleep onset and sleep maintenance, but also in daytime functioning. With the scientific and clinical data we have generated, we believe that we have a unique drug with a potential to have a disruptive impact on the insomnia market once approved by health authorities. Although we will build the core capabilities needed to successfully launch our products ourselves, we are collaborating with Syneos Health on daridorexant in order to effectively reach the primary care market, which accounts for a large volume of insomnia prescriptions. By working together, I believe we can lead the transformation and modernization of the sleep market and bring daridorexant to the millions of people suffering from chronic insomnia.”

[RELATED: Insomnia Linked to Damage in Brain Communication Networks]

Syneos Health is a contract commercial organization (CCO) that leverages its “Syneos One” product development model to accelerate product development and drive asset value for customers.

“We’re pleased to bring our best-in-class commercialization expertise to help daridorexant fulfill its full commercial potential,” says Michelle Keefe, president of Syneos Health Commercial Solutions, in a release. “We view Idorsia as an innovative biopharmaceutical company and have created an innovative, revenue-driven agreement to match, ultimately accelerating growth and reaching patients who need this treatment most.”

Data from the first successful pivotal study was presented at SLEEP 2020. In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia.

Patricia Torr, president and general manager of Idorsia US, says in a release, “During the selection process we found ourselves aligned in our collective vision and strategy for daridorexant. The expertise of the Idorsia commercial organization combined with the sales and customer support capabilities of Syneos Health made our decision to move forward together very easy. Idorsia US now has its leadership team in place, a prime location for our US headquarters, and a pioneering collaboration, the key ingredients to successfully launch our commercial operations.”

Christian Tucat, president of Syneos One, says in a release, “Advanced product development models that offer a modern approach to commercialization matter. Syneos One is looking to bring forward our suite of end-to-end solutions to develop our long-term relationship with Idorsia, starting with the US launch of daridorexant.”